Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 676 results for "celgene corporation headquarters"

Celgene Corporation Elects Mr. Michael W. Bonney to Its Board of Directors
TeleTrader.com

Analysis of Phase II Data for Celgene's Investigational Oral G...

Celgene Corporation (NASDAQ: CELG) has announced that a post-hoc subgroup analysis of a double-blind, placebo-controlled, randomized, multicenter phase II trial of GED-0301 (mongersen) in patients with active Crohn's disease was presented at ... Businessworld India, 4 days ago
[x]  

FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Beta-Thalassemia

SUMMIT, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) and Acceleron Pharma Inc. (NASDAQ:XLRN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designations to ...
 CNBC6 days ago Celgene (CELG) Release: FDA Fast Track Designation Granted To Luspatercept For The Treatment Of Patients With Beta-Thalassemia 5/18/2015  ClinicSpace6 days ago ACCELERON PHARMA : FDA Fast Track Designation Granted to Luspatercept for the Treatment of Patients with Beta-Thalassemia  4 Traders6 days ago Celgene Release: FDA Fast Track Designation Granted To Luspatercept For The Treatment Of Patients With Beta-Thalassemia  BioSpace6 days ago
[x]  
Citybizlist

Celgene To Acquire Quanticel Pharmaceuticals

SUMMIT, N.J. & SAN DIEGO--(BUSINESS WIRE)-- Celgene Corporation (NASDAQ:CELG) and Quanticel Pharmaceuticals, Inc., a privately held biotechnology company focused on cancer drug discovery, today announced a definitive share purchase agreement under ...
 Drug Discovery Online3 weeks ago CELGENE : to Acquire Quanticel Pharmaceuticals  4 Traders3 weeks ago
[x]  

Celgene will collaborate with Astrazeneca to develop PD-L1 inhibitor program for patients with blood cancers

BOUDRY, Switzerland—Celgene International II Sàrl, a wholly owned subsidiary of Celgene Corporation , has entered into a strategic collaboration with MedImmune Limited , a wholly owned subsidiary of AstraZeneca PLC , to develop and commercialize ...
 Drug Discovery News4 weeks ago Celgene Corporation Enters into Strategic Immuno-Oncology Collaboration with AstraZeneca to Develop PD-L1 Inhibitor Program for Patients with Serious Blood Cancers  Minyanville1 month ago Celgene Slaps Down $450 Million Upfront for AstraZeneca PLC's Prized Immunotherapy Blood Cancer Drug  BioSpace1 month ago AstraZeneca enters strategic immuno-oncology collaboration with Celgene Corporation to develop PD-L1 inhibitor programme for patients with serious blood cancers  FierceBiotech1 month ago
[x]  

AstraZeneca : Collaboration with Celgene on PD-L1 in haematology

ASTRAZENECA ENTERS STRATEGIC IMMUNO-ONCOLOGY COLLABORATION WITH CELGENE CORPORATION TO DEVELOP PD-L1 INHIBITOR PROGRAMME FOR PATIENTS WITH SERIOUS BLOOD CANCERS AstraZeneca and MedImmune , the Company's global biologics research and development ...
 4 Traders1 month ago Collaboration with Celgene on PD-L1 in haematology  NASDAQ OMX1 month ago AstraZeneca PLC Collaboration with Celgene on PD-L1 in haematology  ADVFN UK1 month ago
[x]  

Hong Kong Authority Approves Abraxane(R) as First-Line Treatment For Late-Stage Pancreatic Cancer

HONG KONG, March 18,2015 /PRNewswire/ --Celgene announced today that a new treatment option for late-stage pancreatic cancer is now available for use in Hong Kong. Approved by the Department of Health, Abraxane® (paclitaxel formulated as ...
 Yahoo! Finance2 months ago
[x]  

Northern Biologics and Celgene Enter Strategic Collaboration

04/29 07:00 CDT TORONTO, April 29, 2015 Companies to advance first-in-class antibody therapeutics to benefit patients with cancer and fibrosis TORONTO, April 29, 2015 /CNW/ - Northern Biologics Inc., a privately held biotechnology company ...
 Finwin3 weeks ago
[x]  
Business Insider

Why Facebook is the best company to work for in America

Facebook is known for its cool perks, impressive salaries, and great corporate culture. So it's no surprise that it topped Business Insider's 2015 list of the 50 Best Companies To Work For In America , based on exclusive data from PayScale . This ...
 Business Insider India3 weeks ago The 50 best companies to work for in America  Malaysia Chronicle3 weeks ago
[x]  
Citybizlist

CELGENE : CRISPR Therapeutics Gets Additional $64 Million in Funding

CRISPR Therapeutics, a biopharmaceutical company focused on translating CRISPR-Cas9, a breakthrough gene-editing technology into transformative medicines, reported that it recently closed a Series A and Series B financing totaling USD 89 million , ...
 4 Traders2 weeks ago Celgene Joins $64M Financing Round For CRISPR Therapeutics  Citybizlist3 weeks ago Despite Patent Battle Worth Billions, CRISPR Raises $64 Million in Series A & B Rounds  BioSpace3 weeks ago CRISPR Therapeutics Raises Additional $64 Million to Translate Breakthrough CRISPR-Cas9 Technology into Next Generation Therapies for Patients  World Energy Source3 weeks ago
[x]  

M and A Navigator: Deal pipeline -18 May

(M&A Navigator via COMTEX News Network) -- The following is a list of deals covered in detail by M and A Navigator this week: -BELVOIR LETTINGS BUYS UK AGENCY UK lettings franchise Belvoir Lettings plc (AIM: BLV) has acquired Bury, UK-based estate ...
 PredictWallStreet5 days ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - celgene corporation headquarters
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less